-
Focus on independent innovation Nuocheng Jianhua won the 2020 "China Technology Entrepreneurship Association Science and Technology Entrepreneurship Contribution Award"
Time of Update: 2021-07-26
On February 22, 2021, Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969), a biomedical high-tech company, announced today that with strong independent innovation capabilities, the company won the 2020 China Technology Entrepreneurship Association Science and Technology Entrepreneurship Contribution Award .
-
Shanghai Pharmaceuticals: Prolgolimab injection approved for Phase III clinical trial
Time of Update: 2021-07-26
On February 22, Shanghai Pharmaceutical announced that recently, the "Prolgolimab injection" developed by the company's joint venture, Shanghai Pharmaceutical Bokang, received the "Notice of Approval of Drug Clinical Trials" approved and issued by the State Food and Drug Administration .
-
Alfacalcidol soft capsule, a subsidiary of Kunyao Group, passed the consistency evaluation
Time of Update: 2021-07-26
On February 22, Kunming Pharmaceutical Group announced that Kunming Baker Norton Pharmaceuticals, a wholly-owned subsidiary, received the "Drug Supplementary Application Approval Notice" issued by the China Food and Drug Administration on Alfacalcidol Soft Capsules.
Except for Baker Norton, only one domestic pharmaceutical company has passed the consistency evaluation of Alfacalcidol soft capsules .
-
The clinical trial of Exploit Pharmaceuticals Proklamide for the treatment of severely ill patients with new coronary disease completed 588 subjects enrolled in the group
Time of Update: 2021-07-26
The clinical trial recruited 294 male and 294 female patients, and they were included in the "Procruamide + standard treatment" test group and the "placebo + standard treatment" control group at a ratio of 1:1 .
-
Renfu Medicine: Metoprolol Succinate Sustained-Release Tablets Obtained US FDA Approval Number
Time of Update: 2021-07-26
Yichang Renfu submitted an ANDA application for metoprolol succinate sustained-release tablets in 2019, with a cumulative R&D investment of approximately US$1.
According to the website of the National Medical Products Administration, only AstraZeneca AB (hereinafter referred to as "AstraZeneca") obtained drug import registration for metoprolol succinate sustained-release tablets in China.
-
Recent changes in senior personnel in the pharmaceutical industry
Time of Update: 2021-07-26
4. jCyte JCyte appointed Samir Mody as chief commercial officer, and Friedrich Asmus as senior vice president of clinical development and medical affairs .
Asmus previously served as Vice President of Clinical Development at ProQR Therapeutics in ophthalmic biotechnology, while Centeno has held positions at Boston Scientific, Hologic and AltheaDx .
-
Sinopharm: The new crown vaccine for people aged 3 to 17 will be put into use soon
Time of Update: 2021-07-26
, said that this year, the production capacity of Sinopharm China's bio-new crown inactivated vaccine is at the level of 1 billion doses, which can fully supply the market .
In addition, the new crown vaccine suitable for people aged 3-17 will also be put into use soon .
-
Affected by the epidemic, Novartis CEO's annual salary fell to $11.61 million last year
Time of Update: 2021-07-26
Pharmaceutical giant Novartis’s 2020 sales have been affected by the COVID-19 pandemic, and the company’s CEO Vas Narasimhan’s annual salary has also been hit .
In total, the Novartis board paid Narasimhan an annual incentive salary of 2.
-
Wantai Bio: Subsidiary's new crown virus related testing products obtained EU CE certification
Time of Update: 2021-07-25
On February 25th, Wantai Biologics issued an announcement stating that the new coronavirus (2019-nCoV) neutralizing antibody assay kit (magnetic particle chemiluminescence method) produced by its sub
-
The press conference of the Phase III clinical study of Hausen Amela was held in Shanghai
Time of Update: 2021-07-25
The positive results of the Phase III clinical study of Amelo® have provided favorable evidence for China's original third-generation EGFR-TKI targeted therapy drugs in the treatment of first-line EGFR-mutant non-small cell lung cancer.
-
Gan Lai announces that ASC41 oral tablet has been approved by the FDA for clinical trials
Time of Update: 2021-07-25
Melissa Palmer, Chief Medical Officer of Gan Lai, said: “ASC41 is our second NASH project to enter global development after the FXR agonist ASC42 was approved by the US FDA for clinical trials and fast track qualifications.
-
West's Pharmaceuticals announces fourth quarter and full-year 2020 financial results
Time of Update: 2021-07-25
• "Adjusted diluted earnings per share" and "organic sales revenue growth" are non-GAAP financial indicators .
The biologics market segment, led by Flurotec, Westar, Daikyo and NovaPure components, achieved strong double-digit organic sales growth .
-
Yuandong Bio-Caffeine Citrate Injection Passes the Consistency Evaluation of Injection Quality and Efficacy
Time of Update: 2021-07-25
Classification has submitted an application for registration of caffeine citrate injection to the State Food and Drug Administration, and it will be deemed to have passed the consistency evaluation after the pending review is approved .
-
Biocytometer plans to IPO on the Sci-tech Innovation Board and CICC Counseling
Time of Update: 2021-07-25
On the 24th, a reporter from the "Science Innovation Board Daily" learned that Biocytometer (Beijing) Pharmaceutical Technology Co.
plans to go public on the Science and Technology Innovation Board, with CICC acting as a counseling agency .
-
Junshi Bio: EGFR exon 20 insertion and other rare mutation inhibitor JS111 was approved for trial
Time of Update: 2021-07-25
Uncommon EGFR mutations account for about 10% of all EGFR mutations, including EGFRexon 20 insertion, T790M primary point mutation and compound mutation, and G719X represented by the board of directors of the company and all directors guarantee that there is no content in this announcement.
-
Enhua Pharmaceutical: Obtained "Drug Registration Certificate" for 3 specifications of Oxycodone Hydrochloride Injection
Time of Update: 2021-07-25
On February 25, Enhua Pharmaceuticals announced that the company has recently obtained the "Drug Registration Certificate" for 3 specifications of oxycodone hydrochloride injection, which is a controlled drug of hemp Jing, approved and issued by the National Medical Products Administration .
-
Li Fei’s team from Shanghai Xinhua Hospital released a study: a new diuretic, an old drug, can intervene in young children with autism
Time of Update: 2021-07-25
The study found that after 3 months of bumetanide use, the core symptoms of 3-6 years old children with autism, such as social communication disorders and sensory disturbances, have been significantly improved, and the drug is safe and effective .
-
Zhejiang Medicine: Obtained the ARX788 clinical trial approval notice
Time of Update: 2021-07-25
The company initiated a phase I clinical study of ARX788 in the treatment of HER2-positive advanced metastatic gastric cancer and gastroesophageal junction adenocarcinoma in 2019.
-
Puli Pharmaceutical Terlipressin Injection Obtained CBG Marketing Approval
Time of Update: 2021-07-25
Recently, the company received a marketing authorization from the Dutch Drug Evaluation Committee (CBG), which indicates that PlyPharm has the qualification to sell terlipressin injection in the Netherlands, and will guarantee the company's expansion of the company and all members of the board of directors The content is true, accurate and complete, and there are no false records, misleading statements or major omissions .
-
Abandoning U.S. stocks and going to Hong Kong stocks, what benefits might it have for Freshwind Medical, the parent company of United Family Hospital?
Time of Update: 2021-07-25
Reporter | Jin MiaoEdit|Xu Yue On the eve of the Spring Festival of the Year of the Ox, New Frontier Medical, the parent company of United Family Hospital, issued an announcement that the company’s board of directors received a non-binding privatization offer issued by a consortium of buyers including New Frontier Public Holding Limited on February 9, 2021.
